Zacks Investment Research · May 10, 2023
Should You Buy Bellus Health (BLU) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
NASDAQ · BLU
BELLUS Health Inc.
Healthcare · Biotechnology
$14.75
Up+$0.01 (+0.03%)
Updated Aug 15, 2026, 6:37 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.87B
- P/E ratio
- -22.36
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 2.84M
- Avg. volume
- 2.9M
Price performance
BLU price history
1M range · 0 trading sessions · Daily adjusted prices
BLU does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BLU news
The latest Smart Investors Daily articles mentioning BLU.
Stock researchCompany · Overview
BLU research
Overview
Company profile and research snapshot.
Company profile
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2023 | RBC Capital | Sector Perform | — |
| Apr 19, 2023 | Jefferies | Hold | — |
| Apr 19, 2023 | RBC Capital | Sector Perform | — |
| Apr 18, 2023 | Evercore ISI Group | In-Line | — |
| Mar 22, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
The Motley Fool · Apr 26, 2023
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
The Motley Fool · Apr 20, 2023
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK.
Benzinga · Apr 19, 2023
Where BELLUS Health Stands With Analysts
BELLUS Health (NASDAQ:BLU) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 0 0 Last 30D 0 0 2 0 0 1M Ago 1 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 5 analysts have an average price target of $17.05 versus the current price of BELLUS Health at $14.409, implying upside. Below is a summary of how these 5 analysts rated BELLUS Health over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater ...Full story available on Benzinga.com
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
